M.A. Statnick et al. / European Journal of Pharmacology 482 (2003) 139–150
149
opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad.
Sci. U. S. A. 86, 7321–7325.
dines: opioid antagonists with potent anorectant activity. J. Med. Chem.
36, 2842–2850.
Costa, T., Ogino, Y., Munson, P.J., Onaran, H.O., Rodbard, D., 1992.
Drug efficacy at guanine nucleotide-binding regulatory protein-linked
receptors: thermodynamic interpretation of negative antagonism and
of receptor activity in the absence of ligand. Mol. Pharmacol. 41 (3),
549–560.
Moises, H.C., Rusin, K.I., Macdonald, R.L., 1994. Mu and kappa opioid
receptors selectively reduce the same transient components of high-
threshold calcium current in rat dorsal root ganglion sensory neurons.
J. Neurosci. 14, 5903–5916.
Ott, S., Costa, T., 1989. Guanine nucleotide-mediated inhibition of opioid
agonist binding, modulatory effects of ions and of receptor occupancy.
Biochem. Pharmacol. 38 (12), 1931-1939.
Emmerson, P.J., Liu, M.R., Woods, J.H., Medzihradsky, F., 1994. Binding
affinity and selectivity of opioids at mu, delta, and kappa receptors in
monkey brain membranes. J. Pharmacol. Exp. Ther. 271 (3), 1630–1637.
Foote, R.W., Maurer, R., 1982. Autoradiographic localization of opiate n-
receptors in the guinea pig brain. Eur. J. Pharmacol. 85, 99–103.
Fukuda, K., Kato, S., Morikawa, H., Shoda, T., Mori, K., 1996. Functional
coupling of the y, A, and n-opioid receptors to mitogen-activated protein
kinase and arachidonate release in Chinese hamster ovary cells. J. Neu-
rochem. 67, 1309–1316.
Palacios, J.M., Maurer, R., 1984. Autoradiographic localization of drug and
neurotransmitter receptors: focus on the opiate receptor. Acta Histo-
chem. 109, S41–S50.
Pert, C.B., Snyder, S.H., 1974. Opiate receptor binding of agonists and
antagonists affected differentially by sodium. Mol. Pharmacol. 10,
868–879.
Quirion, R., Weiss, A.S., Pert, C.B., 1983. Comparative pharmacological
properties and autoradiographic distribution of [3H]ethylketocyclazo-
cine binding sites in rat and guinea pig brain. Life Sci. 33 (Suppl. 1),
183–186.
Horstman, D.A., Brandon, S., Wilson, A.L., Guyer, C.A., Cragoe Jr., E.J.,
Limbird, L.E., 1990. An aspartate conserved among G-protein receptors
confers allosteric regulation of alpha 2-adrenergic receptors by sodium.
J. Biol. Chem. 265 (35), 21590–21595.
Recant, L., Voyles, N.R., Luciano, M., Pert, C.B., 1980. Naltrexone reduces
weight gain, alters ‘‘h-endorphin’’, and reduces insulin output from pan-
creatic islets of genetically obese mice. Peptides 1 (4), 309–313.
Reinscheid, R.K., Nothacker, H.P., Bourson, A., Ardati, A., Henningsen,
R.A., Bunzow, J.R., Grandy, D.K., Langen, H., Monsma Jr., F.J., Civ-
elli, O., 1995. Orphanin FQ: a neuropeptide that activates an opioid-like
G protein-coupled receptor. Science 270, 792–794.
Itzhak, Y., Hiller, J.M., Simon, E.J., 1984. Solubilization and characteriza-
tion of mu, delta, and kappa opioid binding sites from guinea pig brain:
physical separation of kappa receptors. Proc. Natl. Acad. Sci. U. S. A. 81,
4217–4221.
Jones, R.M., Portoghese, P.S., 2000. 5V-Guanidinonaltrindole, a highly se-
lective and potent n-opioid receptor antagonist. Eur. J. Pharmacol. 396,
49–52.
Reisine, T., 1995. Neurotransmitter receptors. V: Opiate receptors. Neuro-
pharmacology 34 (5), 463–472.
Kenakin, T., 2001. Inverse, protean, and ligand-selective agonism: matters
of receptor conformation. FASEB J. 15, 598–611.
Remmers, A.E., Clark, M.J., Mansour, A., Akil, H., Woods, J.H., Medzih-
radsky, F., 1999. Opioid efficacy in a C6 glioma cell line stably ex-
pressing the human kappa opioid receptor. J. Pharmacol. Exp. Ther. 288
(1), 827–833.
Kieffer, B.L., 1995. Recent advances in molecular recognition and signal
transduction of active peptides: receptors for opioid peptides. Cell. Mol.
Neurobiol. 15 (6), 615–635.
Kong, H., Raynor, K., Yasuda, K., Moe, S.T., Portoghese, P.S., Bell, G.I.,
Reisine, T., 1993. A single residue, aspartic acid 95, in the delta opioid
receptor specifies selective high affinity agonist binding. J. Biol. Chem.
268, 23055–23058.
Robson, L.E., Foote, R.W., Maurer, R., Kosterlitz, H.W., 1984. Opioid
binding sites of the n-type in guinea pig cerebellum. Neuroscience 12
(2), 621–627.
Rothman, R.B., Xu, H., Char, G.U., Kim, A., de Costa, B.R., Rice, K.C.,
Zimmerman, D.M., 1993. Phenylpiperidine opioid antagonists that pro-
mote weight loss in rats have high affinity for the n2B (enkephalin-
sensitive) binding site. Peptides 14, 17–20.
Kosterlitz, H.W., Paterson, S.J., Robson, L.E., 1988. Modulation of binding
at opioid receptors by mono- and divalent cations and by cholinergic
compounds. J. Recept. Res. 8 (1–4), 363–373.
Levine, A.S., Grace, M., Billington, C.J., Zimmerman, D.M., 1991. Central
administration of the opioid antagonist, LY255582, decreases short- and
long-term food intake in rats. Brain Res. 566, 193–197.
Mansour, A., Khachaturian, H., Lewis, M.E., Akil, H., Watson, S.J.,
1987. Autoradiographic differentiation of mu, delta, and kappa
opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7
(8), 2445–2464.
Schmidhammer, H., Smith, C.F.C., Erlach, D., Koch, M., Krassnig, R.,
Schwetz, W., Wechner, C., 1990. Synthesis and biological evaluation
of 14-alkoxymorphinans. 3. Extensive study on cyprodime-related com-
pounds. J. Med. Chem. 33, 1200–1206.
Schmidhammer, H., Jennewein, H.K., Krassnig, R., Traynor, J.R., Patel,
D., Bell, K., Froschauer, G., Mattersberger, K., Jachs-Ewinger, C., Jura,
P., Fraser, G.L., Kalinin, V.N., 1995. Synthesis and biological evalua-
tion of 14-alkoxymorphinans. 11. 3-hydroxycyprodime and analogues:
opioid antagonist profile in comparison to cyprodime. J. Med. Chem.
38, 3071–3077.
Margules, D.L., Moisset, B., Lewis, M.J., Shibuya, H., Pert, C.B., 1978. h-
Endorphin is associated with overeating in genetically obese mice (ob/
ob) and rats (fa/fa). Science 202, 988–991.
Marks-Kaufman, R., Balmagiya, T., Gross, E., 1984. Modifications in food
intake and energy metabolism in rats as a function of chronic naltrexone
infusions. Pharmacol. Biochem. Behav. 20 (6), 911–916.
McKinzie, J.H., Emmerson, P.J., Suter, T.M., Surface, P., Mitch, C., Stat-
nick, M.A., 2001. 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines exhib-
it sodium dependent opioid receptor binding and inverse agonism.
Abstr.—Soc. Neurosci. 27, 310.12.
Schmidt, W.K., 2001. Alvimopan (ADL 8-2698) is a novel peripheral
opioid antagonist. Am. J. Surg. 182, 27S–38S (Suppl.).
Sharif, N.A., Hughes, J., 1989. Discrete mapping of brain mu and delta
opioid receptors using selective peptides: quantitative autoradiography,
species differences and comparison with kappa receptors. Peptides 10,
499–522.
Shaw, W.N., 1993. Long-term treatment of obese Zucker rats with
LY255582 and other appetite suppressants. Pharmacol. Biochem. Be-
hav. 46 (3), 653–659.
Meunier, J.C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvin-
erie, P., Butour, J.L., Guillemot, J.C., Ferrara, P., Monsarrat, B., Ma-
zarguil, H., Vassart, G., Parmentier, M., Costentin, J., 1995. Isolation
and structure of the endogenous agonist of opioid receptor-like ORL1
receptor. Nature 377 (12), 532–535.
Shaw, W.N., Mitch, C.H., Leander, J.D., Mendelsohn, L.G., Zimmerman,
D.M., 1991. The effect of the opioid antagonist LY255582 on body
weight of the obese Zucker rat. Int. J. Obes. 15, 387–395.
Sim, L.J., Childers, S.R., 1997. Anatomical distribution of mu, delta and
kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5V-
O-((-thio)-triphosphate binding in guinea pig brain. J. Comp. Neurol.
386, 562–572.
Mitch, C.H., Zimmerman, D.M., Snoddy, J.D., Reel, J.K., Cantrell, B.E.,
1991. Synthesis and absolute configuration of LY255582, a potent
opioid antagonist. J. Org. Chem. 56, 1660–1663.
Mitch, C.H., Leander, J.D., Mendelsohn, L.G., Shaw, W.N., Wong, D.T.,
Cantrell, B.E., Johnson, B.G., Reel, J.K., Snoddy, J.D., Takemori, A.E.,
Zimmerman, D.M., 1993. 3,4-Dimethyl-4-(3-hydroxyphenyl)piperi-
Wamsley, J.K., 1983. Opioid receptors: Autoradiography. Pharmacol. Rev.
35 (1), 69–83.